RYTM
Rhythm Pharmaceuticals Inc
NASDAQ: RYTM · HEALTHCARE · BIOTECHNOLOGY
$82.12
-2.45% today
Updated 2026-04-29
Market cap
$5.61B
P/E ratio
—
P/S ratio
29.55x
EPS (TTM)
$-3.11
Dividend yield
—
52W range
$55 – $122
Volume
0.9M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A5.5
Quality
C+2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-3.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$137.67
+67.64%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy11 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 36.90% QoQ
Risks
- Altman Z -3.89 — distress zone
- Thin margins at -103.60%
- Negative free cash flow $-26.34M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $23.64M | $77.43M | $130.13M | $189.76M | $189.76M |
| Net income | $-181.12M | $-184.68M | $-260.60M | $-196.54M | $-47.51M |
| EPS | — | — | — | — | $-3.11 |
| Free cash flow | $-177.71M | $-136.20M | $-113.88M | $-116.63M | $-26.34M |
| Profit margin | -766.22% | -238.52% | -200.27% | -103.57% | -103.60% |
Peer comparison
Smart narrative
Rhythm Pharmaceuticals Inc trades at $82.12. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -3.89, it sits in the distress. TTM revenue stands at $189.76M. with profit margins at -103.60%.
Frequently asked questions
What is Rhythm Pharmaceuticals Inc's stock price?
Rhythm Pharmaceuticals Inc (RYTM) trades at $82.12.
Is Rhythm Pharmaceuticals Inc overvalued?
Smart Value Score 30/100 (Grade F, Strong Sell).
What is the price target of Rhythm Pharmaceuticals Inc (RYTM)?
The analyst target price is $137.67, representing +67.6% upside from the current price of $82.12.
What is Rhythm Pharmaceuticals Inc's revenue?
TTM revenue is $189.76M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-3.89 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio29.55x
ROE-90.40%
Beta2.14
50D MA$88.86
200D MA$98.51
Shares out0.07B
Float0.06B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—